Increasing availability of antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has led to decreases in mortality rates. The WHO estimates that 1.7 million deaths were attributable to HIV in 2011 with the majority caused by co-infecting pathogens. Despite a strong initial response to the HIV epidemic, Uganda still has a prevalence rate of 7.2% among adults aged 15-49 according to UNAIDS. Many patients still present late in infection and often co-infected with opportunistic infections such as tuberculosis (TB) and cryptococcal meningitis. Viral hepatitis (B &C) co-infection occurs in 2-10% of HIV-infected individuals and present challenges in terms of best anti-viral treatment, diagnosis, and prevention. As HIV-infected patients live longer on ART, viral hepatitis related cirrhosis and hepatocellular carcinoma which are accelerated by HIV infection will dominate as causes of death in the virally suppressed. The Infectious Diseases Institute (IDI) in Uganda is a Research Center of Excellence and has already established research programs in HIV co-infections under the previous Head of Research (Y. Manabe, Program Director). The current Head of Research (A. Kambugu, Ugandan Program Director) has worked closely with Dr. Manabe for the last 5 years when he was Head of Clinical Services. Basic descriptive epidemiology has already been published in these focal areas at the IDI by rigorously trained PhD students who have been successfully awarded doctoral degrees and who are capable of original scientific investigation. The overarching objective of the program is to train Ugandans to perform locally relevant research in the area of HIV co-infections including tuberculosis, cryptococcal meningitis, and viral hepatitis. This IDI research context and mentorship model will support post-doctoral researchers at the IDI to become fully independent;capable of writing grants and expanding research interests to prevention, improved models of care, new diagnostics evaluations, advanced biostatistical methodology to analyze longitudinal cohorts, and translational basic science research in Uganda through overseas rotations. Four Masters students will be trained at Johns Hopkins Bloomberg School of Public Health in topical areas for which courses are not available at Makerere College of Health Sciences such as health economics, health systems, and translational, basic research in the co-infections listed above. Three Ugandan Masters'students per year will also be supported to fill the pipeline with new researchers. At the end of this 5-year training program, our overarching objective is to solidify a core group of productive, independent scientists who can garner outside funding, continue to mentor others, and be recognized as international, regional leaders in the area of HIV co-infections.
The proposed partnership training program for the Johns Hopkins University Bloomberg School of Public Health in Baltimore and the Infectious Diseases Institute (IDI) in Uganda will train Post-Doctoral Fellows, PhD, and Masters Students who will be mentored by a deep pool of dedicated local and international faculty who have previously engaged in funded, published research in HIV co-infections (tuberculosis, cryptococcal meningitis, and viral hepatitis), regionally relevant research areas for Uganda. At the end of this 5-year training program, our overarching objective is to solidify a core group of productive, independent scientists who can garner outside funding, continue to mentor others, and be recognized as international, regional leaders who are able to influence policy and practice in the area of HIV co-infections.
|Hermans, Sabine M; Babirye, Juliet A; Mbabazi, Olive et al. (2017) Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study. BMC Infect Dis 17:433|
|Ssempijja, Victor; Nakigozi, Gertrude; Chang, Larry et al. (2017) Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis 17:582|
|Sekaggya-Wiltshire, C; von Braun, A; Scherrer, A U et al. (2017) Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother 72:1172-1177|
|Ramachandran, Anu; Manabe, Yukari; Rajasingham, Radha et al. (2017) Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. BMC Infect Dis 17:225|
|Meya, David B; Manabe, Yukari C; Boulware, David R et al. (2016) The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis 29:10-22|
|Kiragga, Agnes N; Nalintya, Elizabeth; Morawski, Bozena M et al. (2016) Implementation and Operational Research: Impact of Nurse-Targeted Care on HIV Outcomes Among Immunocompromised Persons: A Before-After Study in Uganda. J Acquir Immune Defic Syndr 72:e32-6|
|Wekesa, Clara; Asiki, Gershim; Kasamba, Ivan et al. (2016) Atherogenic Risk Assessment among Persons Living in Rural Uganda. J Trop Med 2016:7073894|
|Nakku-Joloba, Edith; Kiragga, Agnes; Mbazira, Joshua Kimeze et al. (2016) Clinical Evaluation of 2 Point-of-Care Lateral Flow Tests for the Diagnosis of Syphilis. Sex Transm Dis 43:623-5|
|Manabe, Yukari C; Worodria, William; van Leth, Frank et al. (2016) Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. Am J Trop Med Hyg 95:1265-1271|
|Meya, David B; Okurut, Samuel; Zziwa, Godfrey et al. (2015) Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis 211:1597-606|
Showing the most recent 10 out of 20 publications